Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

NCT03994783 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Stopped at start of COVID-19 pandemic - non-feasible

Conditions

Kidney Transplant Rejection
Antibody-mediated Rejection

Interventions

DRUG: Rituximab
DRUG: Methylprednisolone
DRUG: Intravenous Immunoglobulin
PROCEDURE: Plasma Exchange

Sponsor

Imperial College London

Collaborators

[object Object]
[object Object]
[object Object]